Can palliative radiotherapy influence prostate-specific antigen response in patients with castrate-resistant prostate cancer treated with systemic therapy(chemotherapy or abiraterone)?——a report of three cases

查看全文 作　　者：Mohan [1]Hingorani;Sanjay [1]Dixit;Pattu [1]Pugazhenthi;Simon [2]Hawkyard;Andrew [2]Robertson;Richard [2]Khafagy 机构地区：[1]Department of Clinical Oncology,Castle Hill Hospital,Hull and East Yorkshire,NHS Trust,Cottingham,East Riding of Yorkshire,HU16 5JQ,UK;[2]Department of Urology,Scarborough District General Hospital 出　　处：《Cancer Biology & Medicine》索引2015年第12卷第1期,共4页 摘　　要：Palliative radiotherapy(pRT) is primarily employed for palliation of bone pain in patients with castrate-resistant prostate cancer(CRPC). However, evidence that p RT influences prostate-specific antigen response in patients with CRPC on systemic therapy is lacking. We describe three cases of CRPC progressing after treatment with docetaxel(n=2) and abiraterone(n=1), who responded unusually after p RT for bone pain with the development of a significant biochemical response and restoration of response to systemic therapy. The possibility of p RT influencing metastatic disease in CRPC has not been previously reported, and raises the possibility of radiation-induced modulation of anti-tumor immune response mechanisms that may play a role in the restoration of response to systemic treatment. 关 键 词：全身治疗 特异性抗原 前列腺癌 报告处理 患者 抗性 去势 比特